Phio Pharmaceuticals Corp (PHIO)
2.8600 -0.0600 (-2.05%)
Phio Pharmaceuticals Corp is a biotechnology company focused on the development of innovative therapies for cancer treatment. The company specializes in leveraging its proprietary delivery platform to enhance the effectiveness of immune-based therapies, particularly in the area of adoptive cell therapy. By utilizing their unique technology, Phio aims to create treatments that can empower the body’s immune system to better target and destroy cancer cells, ultimately improving patient outcomes and offering new hope in the fight against various types of cancer.
Previous Close | 2.920 |
---|---|
Open | 2.930 |
Bid | 2.850 |
Ask | 2.950 |
Day's Range | 2.730 - 2.930 |
52 Week Range | 2.168 - 18.81 |
Volume | 24,898 |
Market Cap | 3.02M |
PE Ratio (TTM) | 0.0830 |
EPS (TTM) | 34.5 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 49,216 |
News & Press Releases
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Marlborough, Massachusetts--(Newsfile Corp. - December 3, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics...
Via Newsfile · December 3, 2024
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
--Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio...
Via Newsfile · November 19, 2024
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Marlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new...
Via Newsfile · November 14, 2024
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Marlborough, Massachusetts--(Newsfile Corp. - November 7, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new...
Via Newsfile · November 7, 2024
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Marlborough Massachusetts--(Newsfile Corp. - November 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new...
Via Newsfile · November 1, 2024
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Marlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via Newsfile · October 24, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 21, 2024
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · October 21, 2024
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via Newsfile · October 18, 2024
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
Marlborough, Massachusetts--(Newsfile Corp. - October 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via Newsfile · October 18, 2024
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
PH-894: Potent and Specific Silencing of BRD4 in NK CellsMarlborough, Massachusetts--(Newsfile Corp. - October 16, 2024) - Phio Pharmaceuticals Corp....
Via Newsfile · October 16, 2024
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · October 10, 2024
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells
INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-TMarlborough, Massachusetts--(Newsfile Corp....
Via Newsfile · October 7, 2024
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Presentation and live Q&A to take place Wednesday, October 9, 2024, at 2 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - October 2,...
Via Newsfile · October 2, 2024
Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference
Marlborough, Massachusetts--(Newsfile Corp. - October 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via Newsfile · October 1, 2024
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society
Marlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via Newsfile · September 25, 2024
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Presentation and live Q&A to take place Tuesday, September 24, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - September 17,...
Via Newsfile · September 17, 2024
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA
Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts--(Newsfile Corp. - September...
Via Newsfile · September 16, 2024
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Conference to be held in New York City September 9-11thMarlborough, Massachusetts--(Newsfile Corp. - September 9, 2024) - Phio Pharmaceuticals Corp....
Via Newsfile · September 9, 2024
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Marlborough, Massachusetts--(Newsfile Corp. - August 29, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via Newsfile · August 29, 2024
PHIO Stock Earnings: Phio Pharma Misses EPS for Q2 2024investorplace.com
PHIO stock results show that Phio Pharma missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 14, 2024
Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Marlborough, Massachusetts--(Newsfile Corp. - August 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via Newsfile · August 14, 2024
Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound
Marlborough, Massachusetts--(Newsfile Corp. - August 6, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via Newsfile · August 6, 2024
Phio Pharmaceuticals Announces New Chief Financial Officer
Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary...
Via Newsfile · August 1, 2024